Class II HLA-DRB4 is a predictive biomarker for survival following immunotherapy in metastatic non-small cell lung cancer.

Sci Rep · 2024 · PMC10764770 · PMID 38172168

Europe PMC DOI

hedged sentence

0.0510

closest p · 1.0× alpha

0.0510

boldest claim

The sentences

approached significancep = 0.051so close (0.05 < p ≤ 0.1)

Multivariable analysis After adjusting for age, gender, race, stage, and histology, HLA-DRB4 was associated with improved OS ( p = 0.011, HR 0.49, 95% CI [0.29, 0.85]) and approached significance for PFS ( p = 0.051, HR 0.61, 95% CI [0.37, 1.00]).

also in 1,426 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.